Michael Eising - ChemoMetec Chief Executive Officer
| CHEMM Stock | DKK 304.00 9.00 3.05% |
CEO
Mr. Michael Eising was appointed Chief Executive Officer of ChemoMetec AS effective as of August 20, 2014. He was Member of the Company Board from July 25, 2013 until October 9, 2014. He was Vice Chairman of the Company Board of Directors until August 20, 2014. He also serves as Member of the Management at Evia Holding ApS. He has experience in business development of technology businesses and financing. since 2017.
| Age | 50 |
| Tenure | 7 years |
| Phone | 45 48 13 10 20 |
| Web | https://chemometec.com |
ChemoMetec Management Efficiency
The company has return on total asset (ROA) of 0.3117 % which means that it generated a profit of $0.3117 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4858 %, meaning that it generated $0.4858 on every $100 dollars invested by stockholders. ChemoMetec's management efficiency ratios could be used to measure how well ChemoMetec manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 1 records | CEO Age | ||
| Jan Winkel | Genmab AS | 62 | |
Management Performance
| Return On Equity | 0.49 | |||
| Return On Asset | 0.31 |
ChemoMetec AS Leadership Team
Elected by the shareholders, the ChemoMetec's board of directors comprises two types of representatives: ChemoMetec inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ChemoMetec. The board's role is to monitor ChemoMetec's management team and ensure that shareholders' interests are well served. ChemoMetec's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ChemoMetec's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christian Berg, Product Manager | ||
| Steen SoendergaardLarsen, Chief Executive Officer | ||
| Kurt Nielsen, Production and Procurement Manager | ||
| Michael Packert, Head of Production | ||
| Kristine Faerch, Director | ||
| Michael Eising, Chief Executive Officer | ||
| Hans Glensbjerg, Vice Chairman of The Board, COO and Director | ||
| Martin Behrens, Chief US | ||
| Christopher MSc, VP US | ||
| Soeren Kjaerulff, Head of Research & Development | ||
| Preben Koenig, Chairman of the Board | ||
| Nils Isbak, Vice President Global Sales | ||
| Steen Sondergaard, Chief Officer | ||
| Claus Madsen, Acting Chief Executive Officer, Chief Financial Officer | ||
| Peter Reich, Independent Director | ||
| Thomas Mogensen, VP of Sales and Marketing-North America | ||
| Lisbet Helles, Head of Marketing | ||
| Sren Kjrulff, Head RD | ||
| Niels Nielsen, Chief Officer | ||
| Martin Glensbjerg, Vice Chairman of the Board, Chief Operating Officer | ||
| Louise Petersen, Quality Manager | ||
| Christopher Runchel, Senior Vice President - United States |
ChemoMetec Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ChemoMetec a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.49 | |||
| Return On Asset | 0.31 | |||
| Profit Margin | 0.39 % | |||
| Operating Margin | 0.50 % | |||
| Current Valuation | 14.38 B | |||
| Shares Outstanding | 17.4 M | |||
| Shares Owned By Insiders | 10.87 % | |||
| Shares Owned By Institutions | 51.35 % | |||
| Price To Earning | 197.96 X | |||
| Price To Book | 40.83 X |
Pair Trading with ChemoMetec
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ChemoMetec position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ChemoMetec will appreciate offsetting losses from the drop in the long position's value.Moving together with ChemoMetec Stock
| 0.64 | PNDORA | Pandora AS | PairCorr |
Moving against ChemoMetec Stock
| 0.55 | MAERSK-A | AP Mller | PairCorr |
| 0.46 | MAERSK-B | AP Mller | PairCorr |
| 0.42 | WIRTEK | Wirtek AS | PairCorr |
The ability to find closely correlated positions to ChemoMetec could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ChemoMetec when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ChemoMetec - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ChemoMetec AS to buy it.
The correlation of ChemoMetec is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ChemoMetec moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ChemoMetec AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ChemoMetec can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ChemoMetec AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for ChemoMetec Stock analysis
When running ChemoMetec's price analysis, check to measure ChemoMetec's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ChemoMetec is operating at the current time. Most of ChemoMetec's value examination focuses on studying past and present price action to predict the probability of ChemoMetec's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ChemoMetec's price. Additionally, you may evaluate how the addition of ChemoMetec to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |